Search Follow us

 

BioPorto is a commercial-stage diagnostic company with a portfolio of antibodies and other products sold for research and diagnostic purposes. However, its lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The test should provide superior results to the standard of care (serum creatinine, sCr) in two hours versus 24 hours or more. We initiate at DKK1,078m or DKK6.93 per share.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs